Back to News
Market Impact: 0.35
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Source: marketbeat.com
Healthcare & BiotechTechnology & Innovation
Arcturus Therapeutics presented preliminary Phase II data for ARCT-810, its mRNA treatment candidate for ornithine transcarbamylase deficiency. The company also plans to incorporate a next-generation delivery platform into the program, potentially improving the candidate's development profile. The update is a modestly positive clinical-development catalyst, though no efficacy or safety figures were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ARCT0.45
More News
- Key AI chip index just broke its long-term trendline. What history says happens next
- Banks, investors grow wary of AI debt, spooked by market selloff
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Why is Nvidia’s Jensen Huang at the centre of a US-China spy scandal?
- CoreWeave confronts 'doom cycle' narrative as neocloud credit risk overshadows growth
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion